Skip Navigation

Annals of Oncology 2007 18(5):813-815; doi:10.1093/annonc/mdm179
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Di Leo, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Leo, A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

editorial

The state of HER-2 status

A Di Leo

"Sandro Pitigliani" Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Italy

(E-mail: adileo@usl4.toscana.it)

The first 150 words of the full text of this article appear below.

This editorial comments on the manuscript reported by Bergqvist et al. [1] who have investigated real-time PCR (RT-PCR) and microarray-based RNA expression (RNA-EP) as alternative strategies to immunohistochemistry (IHC) and in situ hybridization (ISH) for HER-2 testing in breast cancer patients. Bergqvist et al. [1] have compared the performance of ‘standard’ and ‘new’ HER-2 testing tools in a series of ~250 primary breast tumors. Moreover, they have correlated clinical outcomes (relapse-free, breast cancer-related, and overall survival) with HER-2 scores evaluated by the investigated techniques. Bergqvist et al. [1] have to be congratulated for the significant amount of work that has been done and for exhaustively reporting the results of their study.

This editorial will attempt to address two definite questions related to HER-2 testing: (i) in which clinical situation HER-2 testing results are of capital importance for patient's management? (ii) are new HER-2 testing . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?